The science behind nose-to-brain peptides

A question that comes up often in peptide communities: is there a specific way to use a nasal spray, such as spraying at an angle or breathing a certain way, that gets more of a peptide like Semax, Selank, or oxytocin past the nose and into the brain? The short answer is that a real pathway for this exists and has been studied for more than two decades, but no controlled human research supports a home technique like breathing lightly or angling the spray bottle. What the science actually describes is an anatomical route, not a trick.

How the olfactory nerve pathway actually works

The upper part of the nasal cavity contains the olfactory epithelium, a patch of tissue where specialised nerve cells detect smell. Those cells send fibres directly through a bony plate at the base of the skull, called the cribriform plate, into the olfactory bulb, which sits just above the nasal cavity and connects straight into the brain^[1]. A molecule deposited on that patch of tissue can, in principle, travel along those nerve fibres or through the fluid spaces around them and reach brain tissue and cerebrospinal fluid without first entering the bloodstream. A second, smaller route runs through branches of the trigeminal nerve, which also crosses through the nasal lining and connects to the brainstem^[1]. This is why researchers describe nose-to-brain delivery as a way to bypass the blood-brain barrier rather than cross it.

The evidence that this happens in people, not just rodents

The foundational human study, published in 2002, gave healthy adults three different peptides intranasally (a fragment of ACTH, vasopressin, and insulin) and measured them appearing in cerebrospinal fluid within roughly half an hour, while blood levels of the same peptides told a different story. The researchers concluded the peptides reached the brain directly, bypassing the bloodstream^[2]. That finding is the reason nose-to-brain delivery is taken seriously for peptides that cannot easily cross the blood-brain barrier on their own, including the neuropeptides discussed in peptide communities.

Why the rodent data overstates the human effect

Most of the detailed mechanistic work on this pathway, including exactly how much drug reaches which brain region, comes from rats and mice, and the anatomy does not translate cleanly. In rodents, the olfactory epithelium covers roughly 40 to 50 percent of the total nasal surface. In humans, it covers less than 10 percent^[3]. A 2025 review modelling this difference estimated that a mouse brain receives about two orders of magnitude more of a nasally applied compound than a human brain does, for the same relative dose^[3]. That does not mean the human pathway is fake. It means the efficient, well-mapped delivery seen in animal studies is a poor guide to what a person can expect from a store-bought nasal spray.

What about breathing technique or spray angle

There is a real engineering answer to this question, and it is not a home technique. Researchers built a "breath powered" nasal device that seals one nostril and uses the pressure from a person exhaling through a mouthpiece to lift the soft palate, close off the throat, and push the spray past the narrow entrance of the nasal passage toward the olfactory region at the top. In a randomised trial using that device to deliver oxytocin, the engineered airflow was the mechanism, not the user's own breathing pattern^[4]. A standard pump spray, used with an ordinary inhale or exhale, does not reproduce that seal or that airflow. No published human trial has tested whether spraying at a particular angle, or breathing lightly, changes how much peptide reaches the olfactory region with a normal spray bottle, so the specific technique described in community posts has not been validated one way or the other. It is an untested claim, not a debunked one, and it should not be treated as established practice.

Semax, Selank, and oxytocin specifically

Oxytocin is the most heavily studied of the three by far, with more than a decade of intranasal human trials behind it. Even so, a widely cited review of that literature concluded that the neural and physiological mechanisms behind oxytocin's behavioural effects in humans remain poorly understood, which is a real problem for interpreting what any single study shows^[5]. Semax and Selank have far less human data of any kind behind them. Neither has a marketing authorisation from the FDA, EMA, or MHRA, and in the United States, the United Kingdom, and the EU and EEA countries we cover, they are sold only through grey-market vendors with no regulatory oversight of manufacturing or labelling. That regulatory gap matters here specifically because nobody is independently verifying nasal spray formulation, concentration, or delivery device quality for these products.

What we don't yet know

Whether the olfactory pathway makes a meaningful clinical difference for any specific peptide, at any specific dose, delivered through any specific consumer device, is still an open question for most of the compounds discussed in this space. The mechanism is real. The magnitude, in an ordinary person using an ordinary spray, is not well characterised, and the animal data that gets cited most often was generated in noses that are built differently from ours.

This article is for informational and journalistic purposes only and does not constitute medical advice. Decisions about whether to use any peptide product, by any route of administration, belong with a qualified healthcare provider who knows your medical history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.